Cenevo, which specializes in lab management systems, automation, orchestration, data management and AI technology for life sciences, is introducing two new...
Azenta, Inc. announced a strategic partnership with Frontier Space, a pioneer in commercial space-based research systems, to conduct cutting-edge s...
Drug delivery is entering a period of rapid reinvention, driven as much by analytical innovation as by molecular design. In this BioPharma BoardRoo...
As regulators worldwide intensify scrutiny of per- and polyfluoroalkyl substances (PFAS), laboratories are being pushed into a new era of sensitivity, sp...
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), announced a collaboration with the Stanford Center for Definitive and C...
Preliminary results for 2025: Group sales revenue rises by 7.6 percent to around 3.5 billion euros Positive development in both divi...
AI-enabled brown adipose tissue (BAT) phenotype unlocks population-scale human genetic discovery BAT-01 knockdown drives 15% body-weight reduction in ...
Agreement includes eight programmes, including a clinical-ready asset, plus access to advanced AI-driven peptide drug discovery platform and innovati...
First-ever approved treatment for CDD in China now set for commercial launch through dedicated rare disease platform Tenacia Biopharmaceutical...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating tre...
Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel trea...
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, announ...
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseas...
Unlocks path towards registrational Phase 3 trial planned to start in 2026 Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard...
© 2026 Biopharma Boardroom. All Rights Reserved.
